FOXP3 and neoplasm: Anti-TNFR2 monotherapy and combinatory therapy significantly reduced the percentage of Foxp3+ Tregs in CD4+ T cells in tumor tissue, with the combination therapy showing a stronger effect (Figures 7A,B).